12th week of 2016 patent applcation highlights part 8 |
Patent application number | Title | Published |
20160081957 | Agent for Preventing and/or Treating Veisalgia - The object of the present invention is to provide a hangover prophylactic and/or therapeutic agent. The present invention provides a hangover prophylactic and/or therapeutic agent comprising ALAs. | 2016-03-24 |
20160081958 | USE OF METHIONINE SULFOXIMINE TO TREAT DISEASES CAUSED BY AN INFLAMMATORY CYTOKINE RESPONSE - Methods for treating or preventing an inflammatory response comprising administering a diastereomer or diastereomeric mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or diastereomeric mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response. | 2016-03-24 |
20160081959 | METHOD OF USING ARGININE SILICATE INOSITOL COMPLEX FOR WOUND HEALING OR REPAIR - A method for treating a wound or injury in an individual is provided, comprising the steps of administering to the individual afflicted with the wound or injury a composition including an effective amount of arginine silicate inositol (ASI), optionally in combination with another component, and a nutraceutically or pharmaceutically acceptable carrier. | 2016-03-24 |
20160081960 | INHIBITORS OF METALLO- -LACTAMASE-ENZYMES - The present application relates to combination treatments for bacterial infections. For example, the application relates to the use of one or more β-lactam antibiotics and one or more compounds of Formula I: (I) for treatment of a metallo-B-lactamase-expressing bacterial infection or a disease, disorder or condition arising from a metallo-B-lactamase-expressing bacterial infection. | 2016-03-24 |
20160081961 | COMPOSITIONS AND METHODS FOR TREATING NEPHROPATHY - Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat nephropathy, and methods for preparing activated fatty acids are provided herein. | 2016-03-24 |
20160081962 | NUTRITIONAL OR DIETARY SUPPLEMENTS CONTAINING FATTY ACIDS AND NITRITE - Compositions including a fatty acid and a nitrite and/or nitrate composition and methods for using a fatty acid and a nitrite and/or nitrate composition for treatment of various conditions. | 2016-03-24 |
20160081963 | METABOLIC IMPRINTING EFFECTS OF SPECIFICALLY DESIGNED LIPID COMPONENT - The invention relates to the use of specifically designed lipid component with optimal fatty acid profile, an enhanced portion of the palmitic acid residues in the sn-2 position and present as lipid globules with a phospholipid coating for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life. | 2016-03-24 |
20160081964 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides an oral pharmaceutical composition of isotretinoin with reduced food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 2016-03-24 |
20160081965 | ORAL PHARMACEUTICAL COMPOSITION OF ISOTRETINOIN - The present invention provides an oral pharmaceutical composition of isotretinoin with a reduced dose. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention. | 2016-03-24 |
20160081966 | ANTIHYPOXIC PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF - The present invention discloses an antihypoxic pharmaceutical composition and application thereof. The pharmaceutical composition contains vinpocetine and L-carnitine or a derivative thereof and a pharmaceutically acceptable salt thereof, and also can contain trimetazidine or a pharmaceutically acceptable salt thereof. | 2016-03-24 |
20160081967 | COMPOSITIONS OF CHLOROGENIC ACID AND METHODS FOR MAKING AND USING THE SAME IN OBESITY MANAGEMENT - The present invention is directed compositions derived from green coffee bean extract and methods for the use and manufacture of such compositions. The compositions of the invention have unique ratios of chlorogenic acids which offer a therapeutic effect in the treatment of a variety of conditions and disorders. Methods for using the compositions of the invention include, but not limited to, methods for treating obesity and methods for regulating serum lipids. | 2016-03-24 |
20160081968 | COMPOSITION FOR USE IN REDUCING SCAB FORMATION AND PROMOTING HEALING - The present invention relates to a composition comprising at least one mono-glyceride chosen from glyceryl monocaprylate, glyceryl monolaurate and glyceryl monomyristate, and hydrophilic solvent, having a liquid crystalline lamellar structure at a temperature of above about 37° C., a solid crystalline lamellar structure below about 30° C. and a transformation of said solid and liquid crystalline lamellar structures at from about 30° C. to about 37° C., for use in treatment of cuts and wounds, said composition providing a moisturizing effect of said injury or wound, for reducing scab formation and promote healing in connection with injuries or wounds. | 2016-03-24 |
20160081969 | METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS - The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders. | 2016-03-24 |
20160081970 | TREATMENT FOR OBESITY - The present invention relates to a method for treating or preventing obesity in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. The invention further relates to methods for reducing body weight and/or reducing food intake in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds. | 2016-03-24 |
20160081971 | METHOD FOR PRODUCING DOSAGE FORM COMPRISING ODANACATIB - The present invention relates to a method for producing a dosage form, preferably a dosage form for immediate release, containing odanacatib wherein the method comprises the granulation with a specific granulation fluid. The invention further relates to a dosage form obtained according to said method. | 2016-03-24 |
20160081972 | PARENTERAL DOSAGE FORM OF AMIODARONE - The present invention relates to a stable, sterile, ready to administer parenteral dosage form of amiodarone or its pharmaceutically acceptable salt. Particularly, the present invention provides a stable, sterile, ready to administer parenteral dosage form of amiodarone comprising an aqueous solution comprising amiodarone or its pharmaceutically acceptable salt, an acid, and a polyol, wherein the pH of the solution is in the range of about 2.0 to 4.0, wherein the solution is filled in a plastic container and wherein the solution is free of a solubilizer. | 2016-03-24 |
20160081973 | ACTIVATOR OF MITOCHONDRIA - In order to allow differentiation induction of cancer cells into normal cells, the present invention provides an activator of mitochondria containing a component expected to have an epigenetic action, or provides a cell differentiation inducer having a novel composition that has an action to activate mitochondria. The activator of mitochondria contains, as an effective component, 0.03 to 300 μg/mL of a single component of kaempferol, or a mixture component of kaempferol and glycerol. These agents can promote DNA methylation, activate resting genes in cancer cells such as leukemia cells to promote their normal cell division according to the normal cell cycle, and activate mitochondrial functions, to thereby allow continuous differentiation induction into normal cells without arresting the cell differentiation. | 2016-03-24 |
20160081974 | COMPOSITION FOR PREVENTING OR TREATING EDEMA CONTAINING FLAVONOID COMPOUND - Provided is a method of treating edema using a flavonoid compound or a pharmaceutically acceptable salt thereof, and by the method, acquired edema triggered due to cancer treatments can be cured. A composition containing the flavonoid compound is a chemical approach to a conventional physical treatment method, and when the composition is administered to an edema-induced mouse, a considerable reduction in size of edema is observed. | 2016-03-24 |
20160081975 | SOFT GEL COMPOSITIONS AND PRE-GEL CONCENTRATES - Provided are compositions and methods for producing non-aqueous capsule compositions that contain additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including coenzyme Q10, and other oil-based additives. | 2016-03-24 |
20160081976 | FORMULATIONS OF WATER-SOLUBLE DERIVATIVES OF VITAMIN E AND SOFT GEL COMPOSITIONS, CONCENTRATES AND POWDERS CONTAINING SAME - Provided herein are compositions that contain water-soluble vitamin E derivative mixtures (compositions), such as tocopheryl polyethylene glycol succinate (TPGS), TPGS analogs, TPGS homologs and TPGS derivatives. The water-soluble vitamin E mixtures contain mixtures of dimers and monomers of the vitamin E derivative. Provided are products containing the water-soluble vitamin E derivative mixtures, including capsules, soft gel compositions, pre-gel compositions, emulsions and powders. | 2016-03-24 |
20160081977 | PHARMACEUTICAL PREPARATIONS - Pharmaceutical preparations are proposed, comprising bitter-masking acting substances for reducing and/or inhibiting gastric acid secretion induced by food constituents. | 2016-03-24 |
20160081978 | PHARMACEUTICAL COMPOSITION CONTAINING LIRIODENDRON TULIPIFERA L. EXTRACT FOR TREATING CHRONIC MYELOGENOUS LEUKEMIA - The present invention relates to a pharmaceutical composition containing, as an active ingredient, a | 2016-03-24 |
20160081979 | METHOD FOR SEPARATING THERAPEUTIC AGENT FOR CHRONIC MYELOGENOUS LEUKEMIA FROM BARK OF LIRIODENDRON TULIPIFERA L. - The present invention provides a method for separating and preparing a therapeutic agent for chronic myelogenous leukimeia capable of effectively inhibiting growth of T315I, which is known as a mutation of a BCR-ABL fusion gene that causes chronic myelogenous leukemia, comprising the steps of: 1) preliminary extracting by adding ethyl acetate to finely chopped bark of | 2016-03-24 |
20160081980 | Composition Comprising AMD3100 For Preventing or Treating Bone Diseases - The present invention relates to a composition comprising AMD3100 or a pharmaceutically acceptable salt thereof for preventing or treating bone diseases. AMD3100 according to the present invention can effectively prevent or treat of bone diseases by increasing the SDF-1 level in the blood, inducing mobilization of hematopoietic stem/progenitor cell (HSPC) from the bone to the blood, and reducing the deposition of osteoclast on the bone marrow. | 2016-03-24 |
20160081981 | ORGANONITRO THIOETHER COMPOUNDS AND MEDICAL USES THEREOF - The invention provides organonitro thioether compounds, compositions containing such compounds, isolated organonitro thioether compounds and methods for using such compounds and compositions to treat cancer in a patient. Exemplary organonitro thioether compounds described herein include 2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl thioethers and variants thereof. | 2016-03-24 |
20160081982 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C - This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 | 2016-03-24 |
20160081983 | PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE - The present invention relates to the compound (2R,2′R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis. | 2016-03-24 |
20160081984 | Compounds and Compositions That Bind and Stabilize Transthyretin and Their Use for Inhibiting Transthyretin Amyloidosis and Protein-Protein Interactions - Disclosed herein are compounds and compositions thereof which find use in increasing stability of proteins particularly proteins that tend to misfold and form aggregates. Also provided herein are methods for using these compounds and compositions for increasing stability of proteins and thereby decreasing aggregate formation by these proteins. Also disclosed herein are heterobifunctional compounds that include a TTR binding compound connected to a targeting moiety via a linker, for use in disrupting PPIs of a target protein. | 2016-03-24 |
20160081985 | CENICRIVIROC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - The present disclosure relates to pharmaceutical compositions containing cenicriviroc or a salt thereof and optionally one or more additional pharmaceutically active agent, methods for the preparation thereof, and their use in the treatment of diseases or conditions, particularly viruses such as Human Immunodeficiency Virus (HIV). | 2016-03-24 |
20160081986 | LONG-ACTING SPIRO-ISOXAZOLINE ANTIPARASITIC COMPOSITIONS - The invention describes a long-acting composition comprising a spiro-azetidine isoxazoline of Formula (1) or (2) wherein R | 2016-03-24 |
20160081987 | Cysteine Prodrugs - Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease. | 2016-03-24 |
20160081988 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE - Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith. | 2016-03-24 |
20160081989 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors - Compounds according to Formulas I, IA or IB: | 2016-03-24 |
20160081990 | FILM PREPARATION CONTAINING DONEPEZIL-FREE BASE AND METHOD FOR PRODUCING SAME - The present invention provides a method for producing a film which contains a tasteless donepezil-free base, has an appropriate size and thickness, has flexibility for providing stability when handled so as to not easily tear, and has a uniformly dispersed donepezil-free base. In addition, the present invention provides a film containing the donepezil-free base produced through the method. | 2016-03-24 |
20160081991 | FEXOFENADINE MICROCAPSULES AND COMPOSITIONS CONTAINING THEM - The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable drug content and desirable pharmaceutical properties, including a quick dissolution rate of fexofenadine combined with a taste masking effect. | 2016-03-24 |
20160081992 | Sustained Release Aminopyridine Composition - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2016-03-24 |
20160081993 | SUBSTITUTED PHENYLAZOLE DERIVATIVE - Compounds are provided having an excellent hypoglycemic effect and β cell- or pancreas-protecting effects, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition having an excellent therapeutic effect and/or prophylactic effect on type 1 diabetes, type 2 diabetes, and the like, which cause hyperglycemia due to abnormal glucose metabolism. A compound represented by general formula (I), or a pharmaceutically acceptable salt thereof, is disclosed. | 2016-03-24 |
20160081994 | Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side-Effects - The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds. | 2016-03-24 |
20160081995 | Selective NR2B Antagonists - The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. | 2016-03-24 |
20160081996 | Niacin Formulation - The present invention provides a composition including an amphiphilic compound capable of self-assembling into a liquid crystalline phase; and a niacin compound. In another aspect, the present invention provides a method for the treatment of a disease state comprising administering a therapeutically effective amount of a pharmaceutical composition incorporating that composition | 2016-03-24 |
20160081997 | PIPERIDINE/PIPERAZINE DERIVATIVES - The invention relates to a DGAT inhibitor of formula | 2016-03-24 |
20160081998 | USE OF CCR3-INHIBITORS - The present invention relates to CCR3 inhibitors of formula 1, | 2016-03-24 |
20160081999 | SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (Tdp1) - TOPOISOMERASE I (Top1) INHIBITORS - The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds. | 2016-03-24 |
20160082000 | COMPOSITIONS AND METHODS FOR TREATING CARDIOMETABOLIC DISEASES AND DISORDERS - Described herein are combinations useful for treating or preventing a cardiometabolic disease or disorder, or which can be used for appetite suppression, for improvement of endothelial function, for controlling weight, or a combination of one or more thereof. The combinations comprise Berberine, alpha lipoic acid (LA), and apocynin, or an isomer, derivative, pharmaceutically acceptable salt or ester of one or more thereof. Methods of treatment using the combinations, as well as compositions and re lated medical uses are also described. | 2016-03-24 |
20160082001 | TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD - The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. | 2016-03-24 |
20160082002 | METHOD OF REGULATING CARDIAC ARRHYTHMIAS - A method of treating cardiac arrhythmia. The method comprises oral ingestion of liquid comprising quinine, or the stereoisomer quinidine. The liquid, which may be a beverage, is consumed in a volume that provides quinine equivalent to consumption of not less than 2 milligrams and not more than 80 milligrams per day. This dosage has been found to be effective in treating cardiac arrhythmia and inhibiting physiologically damaging atrial fibrillation, and the complications thereof. | 2016-03-24 |
20160082003 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 2016-03-24 |
20160082005 | PROCESS OF MAKING AND USING PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS - In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof. | 2016-03-24 |
20160082006 | PHARMACOLOGICAL TREATMENT OF PARKINSON'S DISEASE - The present invention relates to the co-administration of two neurotransmitter agonists to patients with motor disorders, for the purpose of symptom reduction. In particular the present invention provides methods and compositions for alleviation of akinesia, rigidity and/or tremor associated with Parkinson's disease. | 2016-03-24 |
20160082007 | METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS - The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α | 2016-03-24 |
20160082008 | ERK INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2016-03-24 |
20160082009 | PHARMACEUTICAL PREPARATION COMPRISING PHENYLALANINE DERIVATIVE - The disclosed pharmaceutical preparation comprises a compound represented by the chemical formula (A) or a pharmaceutically acceptable salt thereof, which is dispersed in a matrix consisting of a water-soluble high molecular weight substance; and Crospovidone: | 2016-03-24 |
20160082010 | SALT OF FUSED HETEROCYCLIC DERIVATIVE AND CRYSTAL THEREOF - An objective of the present invention is to improve the solubility of 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylic acid. | 2016-03-24 |
20160082011 | USE OF A DPP-4 INHIBITOR IN PODOCYTES RELATED DISORDERS AND/OR NEPHROTIC SYNDROME - The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP- | 2016-03-24 |
20160082012 | Combination of a PI3 Kinase Inhibitor with Pacitaxel for Use in the Treatment or Prevention of a Cancer of the Head and Neck - A pharmaceutical combination comprising (a) a phosphatidylinositol-3-kinase (PI3K) inhibitor compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof and (b) paclitaxel or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use, for the treatment of a cancer of the head and neck; a pharmaceutical composition comprising said combination; the use of said combination for the preparation of a medicament for the treatment of a cancer of the head and neck; a method of treating or preventing a cancer of the head and neck comprising administering a jointly therapeutically effective amount of such a combination to a subject in need thereof; and a commercial package thereof. | 2016-03-24 |
20160082013 | EMULSION FORMULATIONS OF APREPITANT - Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy. | 2016-03-24 |
20160082014 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS - The present invention relates to methods for modulating the Wnt signaling pathway using compounds of Formula (1), | 2016-03-24 |
20160082015 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS - Methods, compositions, and kits for promoting motor neuron survival and for treatment and diagnosis of neurodegenerative disorders such as Amyotrophic lateral sclerosis (ALS) and Spinal muscular atrophy (SMA) are described herein. | 2016-03-24 |
20160082016 | Use of Clonazepam in Combination with Antibiotic in the Treatment of Bacterially Induced Meningitis - The present invention relates to the use of a well-known benzodiazepine compound, namely clonazepam, in combination with antibiotic agents, for treating bacterially induced meningitis. | 2016-03-24 |
20160082017 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES - The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, more particularly, Th1-mediated (cell-mediated) autoimmune diseases including: multiple sclerosis (MS), rheumatoid arthritis (RA), autoimmune thyroiditis and uveitis. Most preferably the invention is used to treat a patient with a therapeutically effective amount of estriol of 8 milligrams once daily via oral administration to treat the symptoms or prevent the onset of multiple sclerosis. | 2016-03-24 |
20160082019 | Drug Combinations to Treat Cancer - This invention relates to the combination of cabozantinib and abiraterone to treat cancer, particularly castration resistant prostate cancer. | 2016-03-24 |
20160082020 | METHODS AND COMPOSITIONS FOR STIMULATING REEPITHELIALISATION DURING WOUND HEALING - The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mineralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing. | 2016-03-24 |
20160082021 | PHARMACEUTICAL COMPOSITION OF DOXYCYCLINE WITH REDUCED FOOD EFFECT - The present invention relates to a once daily tablet comprising doxycycline at sub-antibiotic dose and one or more pharmaceutically acceptable excipients, wherein the tablet exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline tablet with or without food. A process of preparing the tablet is also provided. | 2016-03-24 |
20160082022 | SACCHARIDES AND SACCHARIDE COMPOSITIONS AND MIXTURES - Described herein are products comprising a xylose (e.g., D-xylose or L-xylose and another sweetener such as glucose). Exemplary products include cosmetic products, oral care products, therapeutic products, nutraceutical products, diagnostic, beverages, animal food products, and human food products. Methods of making the xylose containing products from biomass is provided. | 2016-03-24 |
20160082023 | METHOD OF INHIBITING QUORUM SENSING USING D-GALACTOSE - Provided are a use of D-galactose in inhibition of quorum sensing and/or in prevention and/or treatment of oral bacterial diseases; in particular, a composition for inhibiting quorum sensing and a composition for preventing and/or treating oral bacterial diseases, the composition comprising D-galactose, and a method of inhibiting quorum sensing and a method of preventing and/or treating oral bacterial diseases, the method comprising administering D-galactose. | 2016-03-24 |
20160082024 | USE OF PENTACYCLIC TRITERPENOID SAPONIN COMPOUND FROM SZECHUAN MELANDIUM ROOT FOR PREPARING HYPOGLYCEMIC DRUG - The application of pentacyclic triterpenoid saponins, extracted from the plant of | 2016-03-24 |
20160082025 | USING DNA METHYLTRANSFERASE INHIBITORS TO TREAT CALCIFIC AORTA VALVE DISEASE - Materials and methods for using DNA methyltransferase inhibitors to slow progression of aortic valve calcification and stenosis are provided. | 2016-03-24 |
20160082026 | Ganglioside Transmucosal Formulations - A transmucosal formulation comprising a ganglioside and a mucosal absorption enhancer, as well as a method of treating or preventing Parkinson's disease in a human patient in need thereof comprising parenterally administering such a transmucosal formulation to said patient. | 2016-03-24 |
20160082027 | A COMPOSITION FOR TREATING NEUROPATHY, A PROCESS AND A METHOD OF TREATMENT THEREOF - The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy. | 2016-03-24 |
20160082028 | BIODEFENSES USING TRIAZOLE-CONTAINING MACROLIDES - Use of macrolide and ketolide antibiotics for the treatment of acute exposure and diseases caused by biodefense pathogens is described. | 2016-03-24 |
20160082029 | METHOD TO ENHANCE DELIVERY OF GLUTATHIONE AND ATP LEVELS IN CELLS - A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1′,2′,3′,4′-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue. | 2016-03-24 |
20160082030 | D-AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF HALOGENO PYRIMIDINE COMPOUNDS FOR LIVER DISEASE - Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: | 2016-03-24 |
20160082031 | ANTITUMOR AGENT INCLUDING LOW-DOSE IRINOTECAN HYDROCHLORIDE HYDRATE - Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects. | 2016-03-24 |
20160082032 | THERAPEUTIC EFFECT PREDICTION METHOD FOR COLORECTAL CANCER PATIENT IN WHOM EXPRESSION OF TK1 PROTEIN HAS INCREASED - The present invention provides a method for predicting the therapeutic effect of chemotherapy using an antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising the following steps (1) to (3). As the means for solving the problem, the following invention is provided: a method comprising (1) detecting the expression of TK1 protein by an immunohistochemical method in tumor cells contained in a biological sample obtained from the patient; (2) based on the detection results obtained in step (1), classifying the tumor cells into positive cells and negative cells, and calculating the percentage of positive cells in the tumor cells; and (3) based on the calculation results obtained in step (2), predicting that when the percentage is 30% or more, the patient is likely to sufficiently respond to chemotherapy using the antitumor agent containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5. | 2016-03-24 |
20160082033 | COMPOSITIONS OF SELENOORGANIC COMPOUNDS AND METHODS OF USE THEREOF - The present application relates to compositions comprising selenium compounds, such as 5′-Methylselenoadenosine, a compound of Formula (I), and combinations thereof, and methods of using the same for inhibiting β amyloid aggregation, ApoE4 expression, p38 or Tau protein phosphorylation, or increasing Neprilysin and Insulin Degrading Enzyme expression. | 2016-03-24 |
20160082034 | SiRNA TARGETING ETS1 AND ELK1 AND METHOD OF USING SAME IN THE INHIBITION OF CIP2A GENE IN CANCER TREATMENT - Disclosed are methods of attenuating activity of the gene promoter of CIP2A. siRNAs are used to target against Ets1 and Elk1 transcriptional factors, thereby blocking the binding of Ets1 and Elk1 to the CIP2A gene promoter. It is disclosed that the siRNAs targeted against Ets1 and Elk1 attenuate the gene expression of CIP2A. A kit containing siRNA reagents for attenuating the CIP2A gene expression is also disclosed. | 2016-03-24 |
20160082035 | IMMUNOMODULATING GENE THERAPY - The present invention relates, in general, to Pompe disease and, in particular, to a methods of treating Pompe disease and to compounds/constructs suitable for use in such methods. | 2016-03-24 |
20160082036 | HYDROXYALKYL STARCH FOR THE TREATMENT OF CANCERS BY REDUCTION OF TUMOR GROWTH RATES - The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of cancer, tumor or tumor associated diseases, especially by effectively reducing tumor growth rate and inhibiting tumor growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted. | 2016-03-24 |
20160082037 | COMPOSITION, PREPARATION, AND USE OF CHITOSAN POWDER FOR BIOMEDICAL APPLICATIONS - A powder chitosan-based material can be used for biomedical applications. The chitosan has been treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. A single or multiple such treatments may be employed. For example, the chitosan material may be irradiated under nitrogen using γ-irradiation, treated under a nitrogen plasma, or both. A powder chitosan material can be readily treated by surface modifying treatments such as irradiating under nitrogen using γ-irradiation, treating under a nitrogen plasma, or both. | 2016-03-24 |
20160082038 | TREATMENT OF ARTHRITIS AND OTHER MUSCULOSKELETAL DISORDERS WITH CROSSLINKED HYALURONIC ACID - A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the HA composition includes a crosslinked HA gel that is prepared by reacting an uncrosslinked HA with a biscarbodiimide in the presence of pH buffer in a range of between about 4 and about 8. The composite can optionally include at least one second bioactive agent other than the HA derivative, such as a steroid. | 2016-03-24 |
20160082039 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 2016-03-24 |
20160082040 | NITRIC OXIDE TREATMENT OF MAMMARY TISSUE - Systems, compositions, devices, and methods for treating a mammary condition in a mammal using gNO delivered from a nitric oxide releasing solution (NORS) are disclosed and described. In one embodiment, the mammary condition may be mastitis. | 2016-03-24 |
20160082041 | WEIGHT REDUCING COMPOSITION - The invention relates to soft drink industry, in particular, to dietetic nutrition. The inventive weight reducing composition comprises 0.01-10 mg/l of sodium and 25-150 mg/l of magnesium, the rest being water. Said composition (drinking water) makes it possible to reduce weight without altering the usual eating habits. In addition, consumption of said drinking water results in reduction of weight by 1.2-2.9 kg. | 2016-03-24 |
20160082042 | USE OF MESENCHYMAL STEM CELL-EDUCATED MACROPHAGES TO TREAT AND PREVENT GRAFT VERSUS HOST DISEASE AND RADIATION-INDUCED INJURY - The present invention relates to methods for treating and preventing graft-versus-host disease (GVHD) and radiation-induced tissue damage or organ failure. More particularly, methods of the present invention comprise administering a therapeutically effective amount of mesenchymal stem cell-educated macrophages (MEMs) to a subject to treat or prevent GVHD, bone marrow failure, radiation-induced tissue damage or organ failure, or a condition associated with aberrant inflammation. | 2016-03-24 |
20160082043 | METHODS AND SYSTEMS FOR MULTI-STAGE DRYING OF PLASMA - Disclosed are methods of spray drying blood plasma using a two-step drying process. | 2016-03-24 |
20160082044 | FORMULATIONS AND METHODS FOR CONTEMPORANEOUS STABILIZATION OF ACTIVE PROTEINS DURING SPRAY DRYING AND STORAGE - A method of treatment of plasma with a physiologically compatible spray dry stable acidic substance (SDSAS) prior to or contemporaneously with spray drying of the plasma that results in greater recovery and greater long-term stabilization of the dried plasma proteins as compared to spray dried plasma that has not be subject to the formulation method of the present invention, as well as compositions related to plasma dried by the methods of the present invention. | 2016-03-24 |
20160082045 | Engineering and Delivery of Therapeutic Compositions of Freshly Isolated Cells - The present invention relates to the transient modification of cells. In particular embodiments, the cells are immune systems, such as PBMC, PBL, T (CD3+ and/or CD8+) and Natural Killer (NK) cells. The modified cells provide a population of cells that express a genetically engineered chimeric receptor which can be administered to a patient therapeutically. The present invention further relates to methods that deliver mRNA coding for the chimeric receptor to unstimulated resting PBMC, PBL, T (CD3+ and/or CD8+) and NK cells and which delivers the mRNA efficiently to the transfected cells and promotes significant target cell killing. | 2016-03-24 |
20160082046 | IN VITRO PRODUCTION OF RED BLOOD CELLS WITH SORTAGGABLE PROTEINS - Methods for the in vitro production of enucleated red blood cells and the enucleated red blood cells thus prepared are provided. Such enucleated red blood cells may express a sortaggable surface protein, which allows for surface modification in the presence of a sortase. Also described herein are surface modified enucleated red blood cells, e.g., conjugated with an agent of interest such as a peptide, a detectable label, or a chemotherapeutic agent, and uses thereof in delivering the agent to a subject. | 2016-03-24 |
20160082047 | COMPOSITIONS CONTAINING PLATELET CONTENTS - This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided. | 2016-03-24 |
20160082048 | PLURIPOTENT STEM CELL FOR TREATMENT OF CEREBRAL INFARCTION - An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating cerebral infarction and sequelae associated therewith that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a brain tissue regeneration mechanism by which Muse cells differentiate into nerve cells and the like in damaged brain tissue by administering Muse cells into cerebral parenchyma. | 2016-03-24 |
20160082049 | METHODS, SYSTEMS, AND COMPOSITIONS RELATING TO TREATMENT OF NEUROLOGICAL CONDITIONS, DISEASES, AND INJURIES AND COMPLICATIONS FROM DIABETES - Some embodiments comprise methods, systems, and/or compositions comprising the production and/or use of one or agents selected from a group comprising microRNA-126, a promoter of microRNA-126 expression, a microRNA-126 mimic, cells such as human umbilical cord blood cells (“HUCBCs”), endothelial cells (“EC”), endothelial progenitor cells (“EPC”), and microRNA-126-enriched Exosomes/Microvesicles (“EMVs”) to promote, increase, or improve recovery from conditions, diseases, or injuries and/or function or outcome in a patient in need thereof. | 2016-03-24 |
20160082050 | COMPOSITION, USE THEREOF, AND METHODS OF MANUFACTURING - A composition that includes at least two of: echinochrome A (2-ethyl-3,5,6,7,8-pentahydroxy-1,4-naphthoquinone); spinochrome A (2-acetyl-3,5,6,8-tetrahydroxy-1,4-naphthalenedione); spinochrome B (2,3,5,7-tetrahydroxy-1,4-naphthalenedione); spinochrome C (2-acetyl-3,5,6,7,8-pentahydroxy-1,4-naphthalenedione); spinochrome D (2,3,5,6,8-Pentahydroxy-1,4-naphthalenedione); and spinochrome E (hexahydroxy-1,4-naphthalenedione). The composition can include one or more additional active ingredients (e.g., vitamin, tretinoin (alltrans retinoic acid or ATRA), a glycosaminoglycan (GAG), dermal filler, | 2016-03-24 |
20160082051 | USE OF SEA CUCUMBER GLYCOSAMINOGLYCAN IN PREPARING MEDICINE FOR PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE - The present invention discloses use of sea cucumber glycosaminoglycan in the preparation of drugs. In particular, the present invention relates to use of medical use of sea cucumber glycosaminoglycan, and more particularly to use of depolymerized sea cucumber glycosaminoglycan or natural molecular segments of sea cucumber glycosaminoglycan with a weight average molecular weight greater than 54,500 Da in the preparation of a drug for the prevention and treatment of thromboembolic diseases. Thromboembolic diseases include atherosclerotic thrombotic diseases, venous thromboembolic diseases, hypercoagulable states and postoperative thrombosis or treatment of postoperative thrombi. The present invention has a wide treatment window for thromboembolic diseases, has a higher level of safety, and has good development and research value. | 2016-03-24 |
20160082052 | AGENT FOR THE ANTI-ADHESION OF SKIN PATHOGENIC FLORA - Bacterial agents for preparing compositions which are for cosmetic, pharmaceutical or veterinary use and which are intended to stabilize and/or regulate the cutaneous ecosystem of mammals. These bacterial agents being an extract of a bacterium, or a bacterium, selected for their adhesion to skin cells and anti-adhesive to pathogens of the cutaneous system. The invention also relates to compositions containing such agents. | 2016-03-24 |
20160082053 | BACILLUS BACTERIA FOR USE IN TREATING AND PREVENTING INFECTION IN AQUATIC ANIMALS - Disclosed herein are microbiocidal compositions that include spore-forming strains of | 2016-03-24 |
20160082054 | SYNBIOTIC COMPOSITION FOR INFANTS - There is provided a preparation comprising | 2016-03-24 |
20160082055 | COMPOSITION COMPRISING A COMBINATION OF AN ELDER EXTRACT AND A STRAIN OF LACTOBACILLUS RHAMNOSUS - The present invention concerns a combination of an elder ( | 2016-03-24 |
20160082056 | CANCER THERAPY WITH A PARVOVIRUS COMBINED WITH A BCL-2 INHIBITOR - Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199. | 2016-03-24 |
20160082057 | METHODS AND FORMULATIONS FOR REDUCING ABSORPTION OF CARBOHYDRATES IN A COMPANION ANIMAL - The invention provides methods for reducing absorption of carbohydrates in a companion animal, comprising identifying the companion animal having a health condition or at risk for the health condition associated with high carbohydrate ingestion and feeding a dietary formulation in a therapeutically effective amount to the companion animal. Such dietary formulations can be any of those as described herein. Generally, the dietary formulation can comprise 20% to 60% protein, 10% to 40% fat, 10% to 50% carbohydrates, and 0.01% to 5% alpha-amylase inhibitor. Typically, the therapeutically effective amount can be effective for reducing absorption of carbohydrates in the companion animal as measured by lowering the postprandial blood glucose of the animal as compared to the postprandial blood glucose of the companion animal ingesting a comparable dietary formulation that excludes the alpha-amylase inhibitor. | 2016-03-24 |
20160082058 | METHODS AND FORMULATIONS FOR TREATMENT, REDUCTION, AND PREVENTION OF CANCER IN A COMPANION ANIMAL AND FOR THE REDUCTION OF POSTPRANDIAL BLOOD GLUCOSE IN A COMPANION ANIMAL - The invention provides methods for the treatment of cancer, reduction of cancer risk, or prevention of cancer in a companion animal, comprising: identifying the companion animal having cancer or at risk for cancer and feeding a dietary formulation in a therapeutically effective amount to the animal. The dietary formulation can comprise 20% to 60% protein; 10% to 40% fat; 10% to 50% carbohydrates; and 0.01% to 5% alpha-amylase inhibitor, and optionally 1% to 50% resistant starch. The therapeutically effective amount can be effective for the treatment of cancer, the prevention of cancer, or the reduction of cancer risk in the companion animal by lowering the postprandial blood glucose of the companion animal as compared to the postprandial blood glucose of the companion animal ingesting a comparable dietary formulation that excludes the alpha-amylase inhibitor. | 2016-03-24 |